Neurochemical aftermath of amateur boxing

Archives of Neurology

Volumn 63, Issue 9, 2006, Pages 1277-1280

  Zetterberg, Henrik ^a,d   Hietala, M Albert ^a   Jonsson, Michael ^a   Andreasen, Niels ^b   Styrud, Ewa ^a   Karlsson, Ingvar ^a   Edman, Äke ^a   Popa, Cornel ^a   Rasulzada, Abdullah ^a   Wahlund, Lars Olof ^b   Mehta, Pankaj D ^c   Rosengren, Lars ^a   Blennow, Kaj ^a   Wallin, Anders ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOCHEMICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN;

ADULT; ARTICLE; AXONAL INJURY; BOXING; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; NERVE INJURY; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BOXING; BRAIN CHEMISTRY; CRANIOCEREBRAL TRAUMA; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROFILAMENT PROTEINS; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 33748628239     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.9.1277     Document Type: Article

References (24)

1. Casson IR, Siegel O, Sham R, Campbell EA, Tarlau M, DiDomenico A. Brain damage in modern boxers. JAMA. 1984;251:2663-2667.
2. Martland H. Punch drunk. JAMA. 1928;91:1103-1107.
3. Millspaugh JA. Dementia pugilistica. US Nav Bull. 1937;35:297-303.
4. Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol. 2000;20:179-185.
5. Kemp PL. A critique of published studies into the effects of amateur boxing: why is there a lack of consensus? J R Nav Med Serv. 1995;81:182-189.
6. Haglund Y, Eriksson E. Does amateur boxing lead to chronic brain damage? a review of some recent investigations. Am J Sports Med. 1993;21:97-109.
7. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187-190.
8. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231-245.
9. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49-52.
10. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67:2013-2018.
11. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods. 1994;51:197-204.
12. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673-680.
13. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-105.
14. Friede RL, Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec. 1970;167:379-387.
15. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993;16:460-465.
16. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 2004;1:213-225.
17. Hu YY, He SS, Wang X, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002;160:1269-1278.
18. Hu YY, He SS, Wang XC, et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett. 2002;320:156-160.
19. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004;63:1586-1590.
20. Nylen K, Ost M, Csajbok LZ, et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci. 2006;240:85-91.
21. Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med. 1973;3:270-303.
22. Jellinger KA. Head injury and dementia. Curr Opin Neurol. 2004;17:719-723.
23. Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psychiatry. 1990;53:373-378.
24. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228-234.